Analysts have clear opinions on REPH.

There are 1 analyst offering 12 month price targets for Recro Pharma in the last 3 months. The average price target is $19.00 with a high forecast of $19.00 and a low forecast of $19.00. The average price target represents a 13.13% increase from the last price of $16.80.
Recro Pharma, Inc. (REPH) is followed by 1 analysts on the street.

null from rates it a .

Similarly, null of a with a target of .

The consensus on the street is null.

What does Recro Pharma, Inc.(REPH) do ?
Recro Pharma, Inc. is a pharmaceutical company, which engages in the research and development of non-opioid therapeutics for the treatment of acute post operative pain. It operates through the Acute Care, and Contract Development and Manufacturing (CDMO) business segment. The Acute Care segment focuses on developing innovative products for hospital and related settings. The CDMO segment leverages the company’s formulation expertise to develop and manufacture pharmaceutical products using the company’s proprietary delivery technologies for commercial partners who commercialize or plan to commercialize these products. Its products include Meloxicam, Dexmedetomidine, and Fadolmidine. The company was founded by Geraldine A. Henwood and Thomas F. Henwood on November 15, 2007 and is headquartered in Malvern, PA.

Recro Pharma, Inc. (REPH) Insider Trades

Multiple company employees have indulged in significant insider trading. Recro Pharma, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):

Dir, Ajdler Arnaud : P – Purchase(+$360,000) of REPH in the trading session of 2019-05-17.

Pres, CEO Henwood Geraldine : S – Sale+OE(-$1,287,296) of REPH in the trading session of 2019-05-13.

10% Broadfin Healthcare Master Fund Ltd : S – Sale(-$1,093,182) of Recro Pharma, Inc. in the trading session of 2018-05-24.

Looking for stocks just like REPH?

Based on Wall Street analyst research, several stocks are similar to REPH
They are:
– ZGNX [Info can be found here: ]